Výsledky vyhledávání - "Marcus Matthias, Schittenhelm"

Akademický článek

High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)

Autor: Mihada Bajrami Saipi, Alessia Ruiba, Marcus Matthias Schittenhelm, Gunnar Blumenstock, Balázs Győrffy, Serena Fazio, Marlon Hafner, Anna-Lena Ahrens, Lara Aldinger, Vanessa Aellig, François G. Kavelaars, César Nombela-Arrieta, Falko Fend, Peter J. M. Valk, Driessen Christoph, Kerstin Maria Kampa-Schittenhelm

Publikováno v: Cell Death and Disease, Vol 15, Iss 11, Pp 1-13 (2024)

Abstract Apoptosis-stimulating proteins of p53 (ASPPs) are a family of proteins that modulate key tumor suppressor pathways via direct interaction with p53. Deregulation of these proteins promotes cancer development and impairs sensitivity to systemi

Externí odkaz: https://doaj.org/article/793637dff01642d6878a7b3b72ca88da

Zobrazit plný text záznamu

Akademický článek

Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemiaResearch in context

Autor: Marcus Matthias Schittenhelm, Bianca Walter, Vasileia Tsintari, Birgit Federmann, Mihada Bajrami Saipi, Figen Akmut, Barbara Illing, Ulrike Mau-Holzmann, Falko Fend, Charles Darin Lopez, Kerstin Maria Kampa-Schittenhelm

Publikováno v: EBioMedicine, Vol 42, Iss , Pp 340-351 (2019)

Background: Apoptosis-stimulating Protein of TP53-2 (ASPP2) is a tumor suppressor enhancing TP53-mediated apoptosis via binding to the TP53 core domain. TP53 mutations found in cancers disrupt ASPP2 binding, arguing for an important role of ASPP2 in

Externí odkaz: https://doaj.org/article/162a0dcf7af743ecb55394431c13be11

Zobrazit plný text záznamu

Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Autor: Michael Lübbert, Claudia Schmoor, Tobias Berg, Michael Kruszewski, Marcus Matthias Schittenhelm, Katharina Götze, Caroline Pabst, Andrea Kündgen, Tobias Ma, Anna Frey, Kevin Moschallski, Usama-Ur Rehman, Johannes Jung, Justus Duyster, Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina

Publikováno v: Blood. 140:9087-9088

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::40041dd43a77a085bf42f17e38fe27ea
https://doi.org/10.1182/blood-2022-159471

Zobrazit plný text záznamu

Overexpression of Oncogenic Inhibitory-ASPP (inhibitor of apoptosis stimulating protein of p53) Results in Therapy Resistance and Adverse Outcome in AML

Autor: Marcus Matthias Schittenhelm, Mihada Bajrami Saipi, Gunnar Blumenstock, Peter JM Valk, Balazs Györffy, Kerstin Maria Kampa-Schittenhelm

Publikováno v: Blood. 140:3433-3434

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1bea7e6ad7420a86f2adde1b788f3bc
https://doi.org/10.1182/blood-2022-170405

Zobrazit plný text záznamu

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant

Autor: Kerstin Maria, Kampa-Schittenhelm, Julia, Frey, Lara A, Haeusser, Barbara, Illing, Ashly A, Pavlovsky, Gunnar, Blumenstock, Marcus Matthias, Schittenhelm

Publikováno v: Oncotarget

Activating D816 mutations of the class III receptor tyrosine kinase KIT are associated with the majority of patients with systemic mastocytosis (SM), but also core binding factor (CBF) AML, making KIT mutations attractive therapeutic targets for the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c5283726e8645524484c955fc454d766
https://pubmed.ncbi.nlm.nih.gov/29137311

Zobrazit plný text záznamu